Spinal Muscular Atrophies of Childhood are a group of inherited diseases that cause muscles to weaken and waste away. This affects the nerves that control muscles. There are different types, some starting in infancy, others in childhood.
Every report comes from a Lived member, sent anonymously.
Have you had Noninvasive Ventilation for Spinal Muscular Atrophies of Childhood?
Spinal muscular atrophy (SMA) is a group of inherited diseases that gradually destroy motor neurons, the nerve cells in the spinal cord and lower brain that carry movement signals to the muscles. Without those signals, muscles weaken and waste away. The weakness is usually greatest close to the center of the body, in the trunk, hips, thighs and shoulders, and it can also affect the muscles used for swallowing, coughing and breathing. SMA does not affect intelligence. The childhood forms have traditionally been sorted by when symptoms start and the highest movement milestone a child reaches. Type 1 (Werdnig-Hoffmann disease) is the most common and most severe: weakness appears before 6 months, babies cannot sit without help, and without treatment many do not survive past age 2. Type 2 is usually noticed between 6 and 18 months; children can sit unsupported but cannot stand or walk on their own. Type 3 (Kugelberg-Welander disease) starts after 18 months; children walk independently but may struggle to run, climb stairs or get up from a chair. A rare type 0 begins before birth, and type 4 begins in adulthood. Because treatment now changes what many children achieve, doctors increasingly describe SMA by its genetic results as well as by its type.
Most childhood SMA is caused by changes in a gene called SMN1, which makes the survival motor neuron (SMN) protein that motor neurons need to stay healthy. In most people with SMA, a piece of both copies of SMN1 is missing. A closely related backup gene, SMN2, makes only a small amount of working SMN protein. People have different numbers of SMN2 copies, and more copies generally mean milder disease, which is why the SMN2 count helps predict severity. SMA is inherited in an autosomal recessive pattern: a child is affected only when both parents pass on a changed SMN1 gene. Parents who each carry one changed copy usually do not have SMA themselves. When both parents are carriers, each pregnancy has a 1 in 4 chance of a child with SMA, a 1 in 2 chance of a child who is a carrier, and a 1 in 4 chance of a child who neither has nor carries it. Estimates suggest SMA affects about 1 in 8,000 to 1 in 11,000 people. A few rarer forms are caused by other genes and can follow different inheritance patterns. Carrier testing is available for relatives and for people planning a pregnancy.
In the United States, SMA is part of newborn screening, the heel-prick blood test done shortly after birth, and every state now screens for it. Screening looks for the missing piece of SMN1, so many babies are now identified before any weakness appears. A positive screen is not a diagnosis on its own. A follow-up genetic blood test confirms SMA and counts SMN2 copies, which helps the team judge how severe the disease is likely to be and plan treatment. For a child who already has symptoms, a doctor looks for floppiness (low muscle tone), weakness, delayed or lost motor milestones, and trouble feeding or breathing, then orders the same genetic test, which identifies at least 95% of types 1 to 3. About 5% of people with SMA have a smaller change in SMN1 that standard screening and testing miss, so a child with typical signs and an unexpected result may need gene sequencing. Electromyography (a test of the muscles' electrical activity), nerve conduction studies or a muscle biopsy are used mainly when genetic testing does not explain the symptoms. Families with a known history can also have testing during pregnancy, through chorionic villus sampling or amniocentesis.
There is no cure for SMA, but several treatments now change its course by raising the amount of SMN protein. They protect the motor neurons that remain rather than replacing ones already lost, which is why timing matters so much. Babies treated before symptoms appear do best: in one trial, all 15 infants with three SMN2 copies who received gene therapy within six weeks of birth learned to stand on their own, and 14 walked independently. When treatment starts after weakness has developed, the usual aim is to gain some strength or at least stop further loss, and results depend on age, SMN2 count and how much function remains. Nusinersen (Spinraza) is an antisense oligonucleotide, a short lab-made strand of genetic material that helps the SMN2 gene produce more working protein. It is injected into the spinal fluid by lumbar puncture (spinal tap), with several starting doses and then a dose every four months for as long as it is used, plus blood and urine tests before each dose. Risdiplam (Evrysdi) acts on SMN2 in a similar way but is taken by mouth once a day at home, as a liquid or a tablet. Its common side effects include fever, diarrhea and rash. In animal studies it harmed developing offspring and male reproductive cells, so pregnancy testing, contraception and fertility counseling are part of treatment for teenagers and adults. Gene therapy uses a modified virus that cannot cause infection to deliver a working copy of the SMN1 gene in a single treatment. Onasemnogene abeparvovec (Zolgensma) is given as an intravenous infusion to children under 2, and a version injected into the spinal fluid (Itvisma) is approved for people 2 and older. The main trade-off is liver injury: serious liver damage can occur, and acute liver failure, including deaths, has been reported after the infusion. Patients take a steroid medicine before and after treatment, and liver blood tests continue for at least three months. For people 2 and older who already take nusinersen or risdiplam, apitegromab (Isembyld), approved in 2026, can be added as an infusion every four weeks. It blocks myostatin, a protein that limits muscle growth, and aims to improve muscle strength and function rather than protect nerves. Medicines are only part of care. A specialist team manages breathing support (machines that help clear mucus by imitating a cough, and noninvasive ventilation, air delivered under pressure through a mask, often during sleep), feeding (swallowing assessment and, when needed, a feeding tube), physical and occupational therapy, braces, walking frames and wheelchairs, and the spine. Yearly flu and pneumococcal vaccines are usually recommended.
The course of SMA now depends as much on when treatment began as on the type. Before current treatments, most children with type 1 did not survive early childhood, children with type 2 usually lived into adolescence or young adulthood, and people with type 3 had a typical life expectancy but often found walking harder over time and needed a wheelchair later in life. Outlook has improved, especially for types 1 and 2, and many treated children reach milestones that were once out of reach. Many still live with some weakness, and treatment does not undo damage that happened before it started. Daily life often includes therapy exercises and stretching, mobility equipment, and attention to feeding, breathing and posture. Weak trunk muscles commonly lead to scoliosis (a sideways curve of the spine) and stiff joints, which may need bracing and sometimes surgery. Because learning is not affected, children can take part fully in school and family life when physical needs are supported. Follow-up with a specialist SMA team typically happens every 3 to 6 months to measure strength with standard motor scales, check breathing, swallowing and growth, and judge whether treatment is working. Holding steady can be a meaningful result in a disease that otherwise progresses. Follow-up stays important through the teenage and young adult years, when function can decline even in someone who has seemed stable.
See a doctor soon if a baby seems floppy, has weak kicks or poor head control, feeds poorly, or stops gaining or starts losing motor skills, or if an older child's walking, running or stair climbing is getting harder. A positive newborn screen for SMA needs quick follow-up with a specialist, because treatment works best before symptoms start. Anyone with a family history of SMA who is planning a pregnancy can ask about carrier testing and genetic counseling. For a child with SMA, contact the care team when morning headaches, unusual daytime sleepiness, poor sleep or trouble lying flat suggest the breathing muscles are tiring, or when coughing or choking during meals or poor weight gain suggest swallowing problems. Call the team right away at the start of a cold, cough or fever, since weak breathing and cough muscles make chest infections more dangerous. After gene therapy, call right away for yellowing of the skin or the whites of the eyes, reduced alertness, or a missed or vomited steroid dose. Call 911 if a child is struggling to breathe, is too breathless to talk or cry, or stops breathing.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Spinal Muscular Atrophies of Childhood is like, what's helped you, or ask the community a question.